4D Molecular Therapeutics, Inc.
HealthcareNASDAQ:FDMT · NASDAQ Global Select
-$0.01 today
Vol 0.56M · Avg 0.76M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-27.7%
avg -2.6%
ROIC
-30.2%
avg -40.2%
ROA
-24.7%
avg -33.3%
Analysis
ROA is currently the strongest return metric at -24.7% versus its period average of -33.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
David H. Kirn | Co-Founder, President, CEO & Director | $1.23M | — | 63 | $1.06M | 2.02% |
Fariborz Kamal | Chief Technical Advisor | $892,868.00 | — | 63 | $178,400.00 | 0.34% |
Theresa Janke | Co-Founder & Chief of Staff | $652,315.00 | — | 51 | — | — |
Noriyuki Kasahara | Chief Scientific Advisor & Member of Scientific Advisory Board | $201,288.00 | — | 63 | $22,500.00 | 0.04% |
John F. Milligan | Executive Chairman | $150,000.00 | — | 65 | $33,750.00 | 0.06% |
Kristian Humer | CFO and Principal Financial & Accounting Officer | $116,247.00 | — | 50 | $480,000.00 | 0.92% |
An Song | Chief Translational Medicine Advisor | — | — | — | — | — |
Scott Bizily | Chief Legal Officer & Corporate Secretary | — | — | 54 | $217,000.00 | 0.42% |
Julian Pei | Head of Investor Relations & Corporate Finance | — | — | — | — | — |
Katy Barglow | Chief Technical Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
11
$153,228.38
Net Sentiment
$153,228.38
Net selling
Most Active
Bizily Scott
6 transactions
1–10 of 11
Analysis
Insiders reported 0 buys worth $0.00 and 11 sells worth $153,228.38 over the last 12 months. That adds up to net selling of $153,228.38. Bizily Scott was the most active insider with 6 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | +8.5% | +36.5% (9yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +8.5% over three years. Forward estimates point to Revenue at +36.5% (9yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
KalVista Pharmaceuticals, Inc.
NASDAQ:KALV
$1.44B
Lexicon Pharmaceuticals, Inc.
NASDAQ:LXRX
$852.86M
Omeros Corporation
NASDAQ:OMER
$632.20M
Prothena Corporation plc
NASDAQ:PRTA
$431.91M
REGENXBIO Inc.
NASDAQ:RGNX
$344.31M
Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRA
$329.81M
Bicycle Therapeutics plc
NASDAQ:BCYC
$281.05M
Compass Therapeutics, Inc.
NASDAQ:CMPX
$280.72M
ADC Therapeutics S.A.
NYSE:ADCT
$133.55M
Gossamer Bio, Inc.
GOSS
$38.00M
Who manages FDMT?
4D Molecular Therapeutics, Inc. (FDMT) lists 10 active executives. The top listed executive is John F. Milligan, Executive Chairman.
Are FDMT insiders buying or selling?
Recent insider activity shows net buying of $43.73M.
Explore More
Continue the stock analysis
Jump to another research area for this company.